Vincerx Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	12.06	13.64	18.89	22.58	3.6	0.05
Research & Development	22.62	28.97	49.84	40.08	2.12	-
Operating Expenses	34.68	42.61	68.72	62.66	5.71	0.05
Operating Income	-34.68	-42.61	-68.72	-62.66	-5.71	-0.05
Interest & Investment Income	0.88	1.25	0.66	-	-	-
Other Non Operating Income (Expenses)	-4.14	1.2	7.54	23.35	-5.91	-
EBT Excluding Unusual Items	-37.94	-40.16	-60.52	-39.31	-11.62	-0.05
Merger & Restructuring Charges	-	-	-2.47	-	-	-
Pretax Income	-37.94	-40.16	-62.98	-39.31	-16.62	-0.05
Net Income	-37.94	-40.16	-62.98	-39.31	-16.62	-0.05
Net Income to Common	-37.94	-40.16	-62.98	-39.31	-16.62	-0.05
Shares Outstanding (Basic)	21	21	21	17	5	4
Shares Outstanding (Diluted)	21	21	21	17	5	4
Shares Change (YoY)	1.17%	1.26%	22.43%	227.04%	17.65%	-
EPS (Basic)	-1.78	-1.89	-3.00	-2.29	-3.16	-0.01
EPS (Diluted)	-1.78	-1.89	-3.00	-2.29	-3.16	-0.01
Free Cash Flow	-35.1	-40.45	-59.6	-33.66	-2.28	-
Free Cash Flow Per Share	-1.64	-1.90	-2.83	-1.96	-0.43	-
EBITDA	-34.63	-42.56	-68.67	-62.63	-	-
D&A For EBITDA	0.05	0.05	0.05	0.03	-	-
EBIT	-34.68	-42.61	-68.72	-62.66	-5.71	-0.05

Source: S&P Capital IQ. Standard template.